A novel TP53 variant (rs78378222 A > C) in the polyadenylation signal is associated with increased cancer susceptibility: Evidence from a meta-analysis

Oncotarget

Volumn 7, Issue 22, 2016, Pages 32854-32865

  Wang, Ying ^a   Wu, Xue Song ^b   He, Jing ^c,d   Ma, Tianjiao ^b   Lei, Wei ^a   Shen, Zhen Ya ^a  

^a SOOCHOW UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Apoptosis; GWAS; Polymorphism; Rare variant; TP53

Indexed keywords

ARTICLE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; ESOPHAGUS CARCINOMA; FEMALE; FEMALE GENITAL TRACT CANCER; GENETIC ASSOCIATION; GENETIC VARIATION; GLIOMA; HUMAN; LUNG CANCER; MALE; MELANOMA; MOUTH CANCER; NEUROBLASTOMA; POLYADENYLATION; PROSTATE CANCER; SIGNAL TRANSDUCTION; TP53 GENE; UTERINE CERVIX CANCER; CASE CONTROL STUDY; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; NEOPLASM; ODDS RATIO; PATHOLOGY; PHENOTYPE; REGULATORY RNA SEQUENCE; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

PROTEIN P53; TP53 PROTEIN, HUMAN;

CASE-CONTROL STUDIES; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; ODDS RATIO; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT; RISK FACTORS; RNA 3' POLYADENYLATION SIGNALS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84973558769     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9056     Document Type: Article

References (29)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87-108.
2. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer. 2001; 1:233-240.
3. Li Y, Gordon MW, Xu-Monette ZY, Visco C, Tzankov A, Zou D, Qiu L, Montes-Moreno S, Dybkaer K, Orazi A, Zu Y, Bhagat G, Richards KL, et al. Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013; 121:4529-4540.
4. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007; 445:656-660.
5. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature. 2007; 445:661-665.
6. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol. 2010; 2:a001107.
7. Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, Bisso A, Del Sal G, Syed N, Smith P, Gasco M, Crook T, Lu X. iASPP preferentially binds p53 prolinerich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet. 2006; 38:1133-1141.
8. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 2004; 119:847-860.
9. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004; 119:861-872.
10. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, Hamdi M, van Nes J, Westerman BA, van Arkel J, Ebus ME, Haneveld F, Lakeman A, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature. 2012; 483:589-593.
11. Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, Carter SL, Cibulskis K, Hanna M, Kiezun A, Kim J, Lawrence MS, Lichenstein L, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013; 45:279-284.
12. Gorlov IP, Gorlova OY, Frazier ML, Spitz MR, Amos CI. Evolutionary evidence of the effect of rare variants on disease etiology. Clin Genet. 2011; 79:199-206.
13. Lefevre JH, Bonilla C, Colas C, Winney B, Johnstone E, Tonks S, Day T, Hutnik K, Boumertit A, Soubrier F, Midgley R, Kerr D, Parc Y , et al. Role of rare variants in undetermined multiple adenomatous polyposis and earlyonset colorectal cancer. J Hum Genet. 2012; 57:709-716.
14. Bodmer W, Bonilla C. Common and rare variants in multifactorial susceptibility to common diseases. Nat Genet. 2008; 40:695-701.
15. Stacey SN, Sulem P, Jonasdottir A, Masson G, Gudmundsson J, Gudbjartsson DF, Magnusson OT, Gudjonsson SA, Sigurgeirsson B, Thorisdottir K, Ragnarsson R, Benediktsdottir KR, Nexo BA, et al. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet. 2011; 43:1098-1103.
16. Guan X, Wang LE, Liu Z, Sturgis EM, Wei Q. Association between a rare novel TP53 variant (rs78378222) and melanoma, squamous cell carcinoma of head and neck and lung cancer susceptibility in non-Hispanic Whites. J Cell Mol Med. 2013; 17:873-878.
17. Diskin SJ, Capasso M, Diamond M, Oldridge DA, Conkrite K, Bosse KR, Russell MR, Iolascon A, Hakonarson H, Devoto M, Maris JM. Rare variants in TP53 and susceptibility to neuroblastoma. J Natl Cancer Inst. 2014; 106:dju047.
18. Rao AK, Vinothkumar V, Revathidevi S, Arunkumar G, Manikandan M, Arun K, Rajkumar KS, Ramani R, Ramamurthy R, Munirajan AK. Absence of the TP53 poly-A signal sequence variant rs78378222 in oral, cervical and breast cancers in South India. Asian Pac J Cancer Prev. 2014; 15:9555-9556.
19. Egan KM, Nabors LB, Olson JJ, Monteiro AN, Browning JE, Madden MH, Thompson RC. Rare TP53 genetic variant associated with glioma risk and outcome. J Med Genet. 2012; 49:420-421.
20. Zhou L, Yuan Q, Yang M. A functional germline variant in the P53 polyadenylation signal and risk of esophageal squamous cell carcinoma. Gene. 2012; 506:295-297.
21. Link DC, Schuettpelz LG, Shen D, Wang J, Walter MJ, Kulkarni S, Payton JE, Ivanovich J, Goodfellow PJ, Le Beau M, Koboldt DC, Dooling DJ, Fulton RS, et al. Identification of a novel TP53 cancer susceptibility mutation through wholegenome sequencing of a patient with therapy-related AML. JAMA. 2011; 305:1568-1576.
22. Enciso-Mora V, Hosking FJ, Di Stefano AL, Zelenika D, Shete S, Broderick P, Idbaih A, Delattre JY, Hoang-Xuan K, Marie Y, Labussiere M, Alentorn A, Ciccarino P, et al. Low penetrance susceptibility to glioma is caused by the TP53 variant rs78378222. Br J Cancer. 2013; 108:2178-2185.
23. Tan H, Bao J, Zhou X. Genome-wide mutational spectra analysis reveals significant cancer-specific heterogeneity. Sci Rep. 2015; 5:12566.
24. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr., Kinzler KW. Cancer genome landscapes. Science. 2013; 339:1546-1558.
25. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700.
26. Xue WQ, He YQ, Zhu JH, Ma JQ, He J, Jia WH. Association of BRCA2 N372H polymorphism with cancer susceptibility: a comprehensive review and meta-analysis. Scientific reports. 2014; 4:6791.
27. He J, Liao XY, Zhu JH, Xue WQ, Shen GP, Huang SY, Chen W, Jia WH. Association of MTHFR C677T and A1298C polymorphisms with non-Hodgkin lymphoma susceptibility: evidence from a meta-analysis. Scientific reports. 2014; 4:6159.
28. Begg CB, Berlin JA. Publication bias and dissemination of clinical research. J Natl Cancer Inst. 1989; 81:107-115.
29. Egger M and Smith GD. Bias in location and selection of studies. BMJ. 1998; 316:61-66.